Our Pipeline

Our pipeline contains candidates currently under development either in-house or with our biotechnology and pharmaceutical partners.

Internal Development Programs

Program Indication Preclinical Phase 1 Phase 2 Phase 3 Next Catalyst
XBIO-101 Progesterone Resistant Endometrial cancer
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Interim Phase 2 data expected in 2018
Triple Negative Breast Cancer
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
Planning for biomarker study underway